Acta dermato-venereologica最新文献

筛选
英文 中文
Comparison of Non-insulated Microneedle Fractional Radiofrequency and Ablative Fractional Carbon Dioxide Laser for the Treatment of Facial Atrophic Acne Scarring: A Pilot Randomized Split-face Clinical Study. 非绝缘微针分次射频与烧蚀分次二氧化碳激光治疗面部萎缩性痤疮疤痕的比较:一项随机裂面临床研究。
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-26 DOI: 10.2340/actadv.v105.43611
Le Qu, Sha Sha, Chundi He, Hong-Duo Chen, Yan Wu
{"title":"Comparison of Non-insulated Microneedle Fractional Radiofrequency and Ablative Fractional Carbon Dioxide Laser for the Treatment of Facial Atrophic Acne Scarring: A Pilot Randomized Split-face Clinical Study.","authors":"Le Qu, Sha Sha, Chundi He, Hong-Duo Chen, Yan Wu","doi":"10.2340/actadv.v105.43611","DOIUrl":"https://doi.org/10.2340/actadv.v105.43611","url":null,"abstract":"<p><p>A study was undertaken to compare the effectiveness and adverse effects of non-insulated microneedle fractional radiofrequency (NIMFRF) and ablative fractional carbon dioxide (AFCO2) laser on facial atrophic acne scarring in a randomized split-face model. Thirty subjects with facial atrophic acne scarring were enrolled. Each side of the face randomly received 1 session of NIMFRF or AFCO2 laser. Photographs were taken by VISIA Complexion Analysis System at baseline, 1 month, 2 months, and 6 months after treatments. Subjective evaluations included Échelle d'Évaluation Clinique des Cicatrices d'Acné (ECCA) score, global improve-ment, and self-satisfaction. Potential adverse effects were also recorded. Skin melanin index and ery-thema index were measured. NIMFRF and AFCO2 laser show-ed comparable efficacies on atrophic acne scarring (p > 0.05). ECCA scores decreased significantly at each follow-up visit, compared with baseline (p < 0.05). Approximate 95% of subjects achieved \"satisfied\" or \"very satisfied\" improvement. Pain was more obvious on the AFCO2 laser side. Significantly increased red area value, melanin index and erythema index levels were seen on the AFCO2 laser side at one month or 2 month, compared with the NIMFRF side (p < 0.05). NIMFRF has milder adverse effects with shorter recovery period than AFCO2 laser. NIMFRF may be preferable for some patients due to its favourable adverse effect profile.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43611"},"PeriodicalIF":3.5,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144493363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Risk of Alcohol Addiction and Substance Use Disorders in Darier Disease and Hailey-Hailey Disease. 探索酒精成瘾和物质使用障碍的风险达里尔病和海莉病。
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-25 DOI: 10.2340/actadv.v105.43756
William Jebril, Philip Curman, Berta Olafsdottir, Etty Bachar-Wikström, Jakob Wikström
{"title":"Exploring the Risk of Alcohol Addiction and Substance Use Disorders in Darier Disease and Hailey-Hailey Disease.","authors":"William Jebril, Philip Curman, Berta Olafsdottir, Etty Bachar-Wikström, Jakob Wikström","doi":"10.2340/actadv.v105.43756","DOIUrl":"https://doi.org/10.2340/actadv.v105.43756","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43756"},"PeriodicalIF":3.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hospital Use, Morbidity, and Cancer Risk by Age Group in Neurofibromatosis Type 1: A Nationwide Retrospective Cohort Study. 1型神经纤维瘤病的住院情况、发病率和癌症风险:一项全国回顾性队列研究
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-25 DOI: 10.2340/actadv.v105.43416
Minsu Kim, Suhyun Han, Chong Won Choi, Bo Ri Kim, Sang Woong Youn
{"title":"Hospital Use, Morbidity, and Cancer Risk by Age Group in Neurofibromatosis Type 1: A Nationwide Retrospective Cohort Study.","authors":"Minsu Kim, Suhyun Han, Chong Won Choi, Bo Ri Kim, Sang Woong Youn","doi":"10.2340/actadv.v105.43416","DOIUrl":"https://doi.org/10.2340/actadv.v105.43416","url":null,"abstract":"<p><p>Neurofibromatosis type 1 (NF1) affects multiple organs progressively, leading to a shortened life expectancy. This study aimed to identify the complications that are prominent in each age group by comparing 28,082 patients with NF1 and 84,246 matched controls. Benign and malignant neoplasms along with neurological complications were the primary contributors to hospital use across most age groups. Respiratory and circulatory disorders were a common cause of hospital use in children and older adults, respectively. Except for soft tissue and central nervous system-originated malignancies, which are well-established NF1-related tumours, the highest rate ratios (RR) of malignancies with statistical significance was observed in the adrenal gland (0-9 years, RR 50.67, 95% CI 6.74-380.76); female genital organs (10-14 years, RR 12.06, 95% CI 1.35-107.93); respiratory and intrathoracic organs (15-19 years, RR 15.10, 95% CI 1.76-129.22; 20-29 years, RR 7.59, 95% CI 2.94-19.56; ≥ 60 years, RR 1.38, 95% CI 1.18-1.61); lip, oral cavity, and pharynx (30-39 years, RR 6.11, 95% CI 1.53-24.42); and bone and articular cartilage (40-49 years, RR 3.06, 95% CI 1.37-6.81; 50-59 years, RR 4.73, 95% CI 2.35-9.50). Comorbidities and malignancies that predominantly affect patients vary by age group; physicians should be aware of the appropriate management strategies throughout their lifespan.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43416"},"PeriodicalIF":3.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Asthma and Asthma Severity Among Patients with Moderate-Severe Atopic Dermatitis Treated with Advanced Systemics. 先进系统治疗中重度特应性皮炎患者哮喘患病率和哮喘严重程度
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-25 DOI: 10.2340/actadv.v105.43415
Maria O Christensen, Ida Vittrup, Jesper Elberling, Lone Skov, Charlotte G Mortz, Lotte Themstrup, Maiken G Dalager, Kristina S Ibler, Ann Haerskjold, Simon F Thomsen, Christian Vestergaard
{"title":"Prevalence of Asthma and Asthma Severity Among Patients with Moderate-Severe Atopic Dermatitis Treated with Advanced Systemics.","authors":"Maria O Christensen, Ida Vittrup, Jesper Elberling, Lone Skov, Charlotte G Mortz, Lotte Themstrup, Maiken G Dalager, Kristina S Ibler, Ann Haerskjold, Simon F Thomsen, Christian Vestergaard","doi":"10.2340/actadv.v105.43415","DOIUrl":"https://doi.org/10.2340/actadv.v105.43415","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43415"},"PeriodicalIF":3.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144482826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Control of Refractory Hidradenitis Suppurativa with Spesolimab: A Case Report. Spesolimab成功控制难治性化脓性汗腺炎1例。
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-23 DOI: 10.2340/actadv.v105.43329
Yangfan Lai, Yanzhuo Hu, Xiaoyao Fan, Baishuang Yue, Ying Ma
{"title":"Successful Control of Refractory Hidradenitis Suppurativa with Spesolimab: A Case Report.","authors":"Yangfan Lai, Yanzhuo Hu, Xiaoyao Fan, Baishuang Yue, Ying Ma","doi":"10.2340/actadv.v105.43329","DOIUrl":"https://doi.org/10.2340/actadv.v105.43329","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43329"},"PeriodicalIF":3.5,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Male Androgenetic Alopecia with Psychosocial and Sexual Well-being in Early Middle-aged Men: A Northern Finland Birth Cohort 1986 Study. 男性雄激素性脱发与中年早期男性社会心理和性健康的关系:1986年芬兰北部出生队列研究。
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-23 DOI: 10.2340/actadv.v105.43457
Arttu Järvinen, Jari Jokelainen, Laura Huilaja, Suvi-Päivikki Sinikumpu
{"title":"Association of Male Androgenetic Alopecia with Psychosocial and Sexual Well-being in Early Middle-aged Men: A Northern Finland Birth Cohort 1986 Study.","authors":"Arttu Järvinen, Jari Jokelainen, Laura Huilaja, Suvi-Päivikki Sinikumpu","doi":"10.2340/actadv.v105.43457","DOIUrl":"https://doi.org/10.2340/actadv.v105.43457","url":null,"abstract":"<p><p>Androgenetic alopecia is the most common type of hair loss in men. It is reported to have a strong effect on the quality of life, especially at a young age. However, there are only a few studies evaluating the relationship between androgenetic alopecia and psychosocial well-being in the general population. This study examined the association of androgenetic alopecia and its severity with psychosocial symptoms and sexual issues at a population level in male subjects aged between 33 and 35 years belonging to the Northern Finland Birth Cohort 1986 Study (NFBC1986) (n = 1,027). During 2019 to 2020, cohort subjects participated in a large follow-up study and completed diverse health questionnaires, including information on their hair status, psychosocial symptoms (the Hopkins Symptom Checklist-25 [HSCL-25] and the Generalized Anxiety Disorder Screener [GAD-7]) and sexual health. Androgenetic alopecia was reported as follows: No androgenetic alopecia n = 468 (45.6%), mild n = 435 (42.4%), moderate n = 62 (6.0%), and severe androgenetic alopecia n = 62 men (6.0%). There was no significant association of androgenetic alopecia presence or its severity with depression, anxiety, or sexual symptoms. In conclusion, contrary to previous findings, a relationship between androgenetic alopecia and psychosocial problems in early midlife was not found.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43457"},"PeriodicalIF":3.5,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144473660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Progressive Improvement of Atopic Dermatitis by an Herbal Emollient Plus Combination in a 12-week Clinical Trial. 在一项为期12周的临床试验中,草药润肤剂加复方对特应性皮炎的长期进行性改善。
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-18 DOI: 10.2340/actadv.v105.43026
Lars Herrmann, Stanislav Andreev, Ramona Ziegler, Christine Neubauer, Kathrin Moritz, Nicole Maehler, Hubert Steindl, Stephan Daehnhardt-Pfeiffer, Christoph Abels
{"title":"Long-term Progressive Improvement of Atopic Dermatitis by an Herbal Emollient Plus Combination in a 12-week Clinical Trial.","authors":"Lars Herrmann, Stanislav Andreev, Ramona Ziegler, Christine Neubauer, Kathrin Moritz, Nicole Maehler, Hubert Steindl, Stephan Daehnhardt-Pfeiffer, Christoph Abels","doi":"10.2340/actadv.v105.43026","DOIUrl":"10.2340/actadv.v105.43026","url":null,"abstract":"<p><p>Atopic dermatitis is a chronic inflammatory skin disease characterized by flare-ups of inflamed, dry, and itchy skin affecting over 200 million people worldwide. \"Emollients plus\" containing active cosmetic ingredients such as herbal extracts and phytochemicals have the potential to surpass the efficacy of conventional emollients, while avoiding side effects associated with pharmacological interventions. The reported 12-week clinical trial (NCT05790083) evaluated long-term efficacy and tolerability of oil-in-water emulsions BNO 3731 and BNO 3732 containing ginger extract and cannabidiol as basic emollient therapy for atopic dermatitis. A total of 100 adults and children with a history of atopic dermatitis were included and applied BNO 3732 (body lotion) twice daily and BNO 3731 (intensive care product) as needed. Over 12 weeks the emollients plus combination led to sustained improvement of peak pruritus and patient-reported outcome measures, i.e., \"Recap of atopic eczema\". Objective dermatological evaluation showed progressive improvements for vIGA-ADTM and isolated symptoms, i.e., erythema and dryness. Instrumental analysis of intercellular lipid contents and lipid lamellae organization in the stratum corneum demonstrated recovery of the epidermal barrier integrity. The clinical results provide evidence on the efficacy of herbal emollients plus beyond mere moisturizing and occlusive properties. BNO 3731 and BNO 3732 were very well tolerated.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43026"},"PeriodicalIF":3.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis. 不同种类生物制剂治疗牛皮癣的实际成本。
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-18 DOI: 10.2340/actadv.v105.42767
Linda T H Godding, Marieke M B Seyger, Albert Duvetorp, Marisol E Otero, Paul M Ossenkoppele, Annet M Oostveen, M Birgitte Visch, Ella A M Van der Voort, John E M Körver, Lizelotte J M T Weppner-Parren, Maartje A M Berends, W Peter Arnold, Sharon R P Dodemont, Astrid L A Kuijpers, Johannes M Mommers, Femke M Homan, Antoni H Gostynski, Berit Velstra, Marloes M Kleinpenning, Martijn B A Van Doorn, Romy R M C Keijsers, Else N Kop, Inge M Haeck, Judith H J Hendricksen-Roelofzen, Douwe Vellinga, Elke M G J De Jong, Juul M P A Van den Reek
{"title":"Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis.","authors":"Linda T H Godding, Marieke M B Seyger, Albert Duvetorp, Marisol E Otero, Paul M Ossenkoppele, Annet M Oostveen, M Birgitte Visch, Ella A M Van der Voort, John E M Körver, Lizelotte J M T Weppner-Parren, Maartje A M Berends, W Peter Arnold, Sharon R P Dodemont, Astrid L A Kuijpers, Johannes M Mommers, Femke M Homan, Antoni H Gostynski, Berit Velstra, Marloes M Kleinpenning, Martijn B A Van Doorn, Romy R M C Keijsers, Else N Kop, Inge M Haeck, Judith H J Hendricksen-Roelofzen, Douwe Vellinga, Elke M G J De Jong, Juul M P A Van den Reek","doi":"10.2340/actadv.v105.42767","DOIUrl":"10.2340/actadv.v105.42767","url":null,"abstract":"<p><p>Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab's and ustekinumab's originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv42767"},"PeriodicalIF":3.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk of Death, Infections, and Hyperthermia in Ectodermal Dysplasias: A Nationwide Study. 外胚层发育不良患者的死亡、感染和热疗风险:一项全国性研究。
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-18 DOI: 10.2340/actadv.v105.43101
Laura Krogh Herlin, Sigrún A J Schmidt, Trine H Mogensen, Mette Sommerlund
{"title":"Risk of Death, Infections, and Hyperthermia in Ectodermal Dysplasias: A Nationwide Study.","authors":"Laura Krogh Herlin, Sigrún A J Schmidt, Trine H Mogensen, Mette Sommerlund","doi":"10.2340/actadv.v105.43101","DOIUrl":"10.2340/actadv.v105.43101","url":null,"abstract":"<p><p>This nationwide population-based study investigated the risk of death, infections, and hyperthermia in Danish patients with ectodermal dysplasia (ED). A validated cohort of ED patients (n = 396) and matched population comparators (n = 3960) was compared to assess these risks before (case-control analysis) and after ED diagnosis (cohort analysis). Using matched comparators as a reference, the overall hazard ratio (HR) for death was 1.33 (95% confidence interval [CI] 0.70-2.55) in ED patients, and particularly high in males with hypohidrosis (HR 3.77, 95% CI 1.57-9.03) and individuals diagnosed before age 18 (HR 6.53, 95% CI 1.84-23.13). ED was associated with an increased risk of hospital-diagnosed infections before (odds ratio [OR] 2.27, 95% CI 1.81-2.85) and after (HR 2.06, 95% CI 1.74-2.45) diagnosis, varying across subtypes. Sensitivity analyses supported these findings, e.g., using antimicrobial prescriptions to identify infections. An association between hypohidrosis and previous hyperthermia (OR 7.11, 95% CI 3.26-15.51) diminished after diagnosis (HR 1.38, 95% CI 0.54-3.53). This study found an increased mortality risk in males with hypohidrosis and those diagnosed in childhood, and infection and hyperthermia risks depending on ED subtype. These data enhance understanding of ED's clinical course, informing patient management and counselling.</p>","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43101"},"PeriodicalIF":3.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144324139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment. 杜匹单抗治疗后持续性瘙痒或病变需要奈莫单抗治疗的结节性痒疹4例
IF 3.5 4区 医学
Acta dermato-venereologica Pub Date : 2025-06-16 DOI: 10.2340/actadv.v105.43419
Yoshihito Mima, Masako Yamamoto, Ken Iozumi
{"title":"Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment.","authors":"Yoshihito Mima, Masako Yamamoto, Ken Iozumi","doi":"10.2340/actadv.v105.43419","DOIUrl":"10.2340/actadv.v105.43419","url":null,"abstract":"","PeriodicalId":6944,"journal":{"name":"Acta dermato-venereologica","volume":"105 ","pages":"adv43419"},"PeriodicalIF":3.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信